Literature DB >> 10051746

Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases.

R E Goodchild1, J A Court, I Hobson, M A Piggott, R H Perry, P Ince, E Jaros, E K Perry.   

Abstract

It is now widely recognized that histamine acts as a neurotransmitter in the mammalian central nervous system. Three selective histamine receptors have been described, all of which are present in the basal ganglia. This study is a detailed, quantitative, autoradiographical examination of the densities of histamine H3-receptors in coronal sections of human basal ganglia, using the selective ligand [3H]-(R)-alpha-methylhistamine. [3H]-(R)-alpha-methylhistamine binding was highest within the external and internal segments of the globus pallidus together with the substantia nigra. High levels were also found in the striatum, where density was significantly higher (P < 0.05) at a pre-, as opposed to post-, anterior commissure coronal level. Within the striatum, binding was noticeably higher in both the nucleus accumbens and acetylcholinesterase-deficient striosomes, while being undetectable in the subthalamic nucleus and very low in both the ventroanterior and ventrolateral thalamic nuclei. An intermediate level of binding, often with a laminar distribution, was seen in the insular cortex. [3H]-(R)-alpha-methylhistamine binding was also examined in both Parkinson's disease and Huntington's disease. No difference from control receptor density was found in any area examined in Parkinson's disease, while values were significantly lower in caudate (P < 0.001), putamen (P < 0.001), external (P < 0.001) and internal (P < 0.05) globus pallidus, although not the insular cortex, in Huntington's disease cases. These data suggest that H3-receptors are present upon striatonigral projection neurons of the direct and indirect movement pathways thus providing histaminergic control over the activity of both these circuits.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051746     DOI: 10.1046/j.1460-9568.1999.00453.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  16 in total

1.  [(11)C]TASP457, a novel PET ligand for histamine H3 receptors in human brain.

Authors:  Yasuyuki Kimura; Chie Seki; Yoko Ikoma; Masanori Ichise; Kazunori Kawamura; Keisuke Takahata; Sho Moriguchi; Tomohisa Nagashima; Tatsuya Ishii; Soichiro Kitamura; Fumitoshi Niwa; Hironobu Endo; Makiko Yamada; Makoto Higuchi; Ming-Rong Zhang; Tetsuya Suhara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-23       Impact factor: 9.236

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 3.  Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.

Authors:  Laurie Galvan; Véronique M André; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  J Huntingtons Dis       Date:  2012

4.  Thioperamide, an H₃ receptor antagonist prevents [³H]glucose uptake in brain of adult rats lesioned as neonates with 5,7-dihydroxytryptamine.

Authors:  Jadwiga Jośko; Jacek Drab; Przemysław Nowak; Ryszard Szkilnik; Eva Körossy; Dariusz Boroń; Halina Brus; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

5.  Ontogenetic serotoninergic lesioning alters histaminergic activity in rats in adulthood.

Authors:  Jadwiga Jośko; Jacek Drab; Jerzy Jochem; Przemysław Nowak; Ryszard Szkilnik; Eva Korossy-Mruk; Dariusz Boroń; Richard M Kostrzewa; Halina Brus; Ryszard Brus
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

6.  The histamine autoreceptor is a short isoform of the H₃ receptor.

Authors:  F Gbahou; A Rouleau; J-M Arrang
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

7.  Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.

Authors:  Catherine Pillot; Jordi Ortiz; Anne Héron; Sophie Ridray; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Authors:  M Uguen; D Perrin; S Belliard; X Ligneau; P M Beardsley; J M Lecomte; J C Schwartz
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Histaminergic activity in a rodent model of Parkinson's disease.

Authors:  Przemysław Nowak; Lukasz Noras; Jerzy Jochem; Ryszard Szkilnik; Halina Brus; Eva Körossy; Jacek Drab; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2009-02-28       Impact factor: 3.911

10.  Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions.

Authors:  Christian Brabant; Livia Alleva; Thierry Grisar; Etienne Quertemont; Bernard Lakaye; Hiroshi Ohtsu; Jian-Sheng Lin; Peter Jatlow; Marina R Picciotto; Ezio Tirelli
Journal:  Psychopharmacology (Berl)       Date:  2008-10-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.